PL2285786T3 - Pochodne chinoksalinodionowe - Google Patents

Pochodne chinoksalinodionowe

Info

Publication number
PL2285786T3
PL2285786T3 PL09765489T PL09765489T PL2285786T3 PL 2285786 T3 PL2285786 T3 PL 2285786T3 PL 09765489 T PL09765489 T PL 09765489T PL 09765489 T PL09765489 T PL 09765489T PL 2285786 T3 PL2285786 T3 PL 2285786T3
Authority
PL
Poland
Prior art keywords
quinoxalinedione derivatives
quinoxalinedione
derivatives
Prior art date
Application number
PL09765489T
Other languages
English (en)
Inventor
Daniel Cravo
Sophie Hallakou-Bozec
Franck Lepifre
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL2285786T3 publication Critical patent/PL2285786T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09765489T 2008-06-16 2009-05-19 Pochodne chinoksalinodionowe PL2285786T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290564 2008-06-16
EP09765489.1A EP2285786B1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives
PCT/EP2009/003538 WO2009152909A1 (en) 2008-06-16 2009-05-19 Quinoxalinedione derivatives

Publications (1)

Publication Number Publication Date
PL2285786T3 true PL2285786T3 (pl) 2014-01-31

Family

ID=40823394

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09765489T PL2285786T3 (pl) 2008-06-16 2009-05-19 Pochodne chinoksalinodionowe

Country Status (24)

Country Link
US (2) US8329698B2 (pl)
EP (1) EP2285786B1 (pl)
JP (1) JP5596676B2 (pl)
KR (1) KR101641391B1 (pl)
CN (1) CN102066342B (pl)
AR (1) AR072148A1 (pl)
AU (1) AU2009259754B2 (pl)
BR (1) BRPI0915064B8 (pl)
CA (1) CA2728018C (pl)
CO (1) CO6321252A2 (pl)
CY (1) CY1114737T1 (pl)
DK (1) DK2285786T3 (pl)
EA (1) EA020236B1 (pl)
EC (1) ECSP11010760A (pl)
ES (1) ES2436195T3 (pl)
HR (1) HRP20131069T1 (pl)
IL (1) IL209421A (pl)
MX (1) MX2010013577A (pl)
MY (1) MY155695A (pl)
NZ (1) NZ590503A (pl)
PL (1) PL2285786T3 (pl)
PT (1) PT2285786E (pl)
SI (1) SI2285786T1 (pl)
WO (1) WO2009152909A1 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
MX371331B (es) 2012-04-24 2020-01-27 Vertex Pharma Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
ME03336B (me) 2013-03-12 2019-10-20 Vertex Pharma Inhibitori dnk-pk
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
CN103435561B (zh) * 2013-08-19 2016-08-10 上海交通大学 一种新型d-氨基酸氧化酶抑制剂及其制备和应用
JP6408569B2 (ja) 2013-10-17 2018-10-17 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
EP3518931A4 (en) 2016-09-27 2020-05-13 Vertex Pharmaceuticals Incorporated METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
EP3941496A4 (en) * 2019-03-18 2022-11-23 University of Washington METHODS OF PROMOTING CELLULAR MATURATION WITH AMPK ACTIVATORS
CN110642798B (zh) * 2019-11-10 2020-07-24 湖南科技学院 一种n-取代-1,4-二氢-2,3-喹喔啉二酮化合物的绿色合成方法
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
KR102682398B1 (ko) * 2020-11-26 2024-07-05 주식회사 엘지화학 다이아실글리세롤 키나아제 저해제로서 헤테로사이클 화합물 및 이의 용도
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631373A (en) * 1993-11-05 1997-05-20 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones
HUP0001311A3 (en) 1997-02-18 2001-07-30 American Home Products Corp Ma 5-aminoalkoxy-1,4-dihydroquinoxaline-2,3-diones being dopamine agonists and pharmaceutical compositions containing them
AU2002314101A1 (en) * 2001-05-25 2002-12-09 Boehringer Ingelheim Pharma Gmbh &Co. Kg Combination of a dopamine d2-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways
DE602004007693T2 (de) 2004-01-06 2008-06-05 Janssen Pharmaceutica N.V. (3-oxo-3,4-dihydro-chinoxalin-2-yl-amino)-benzamid-derivate und verwandte verbindungen als glykogen-phosphorylase-hemmer zur behandlung von diabetes und adipositas
MY139645A (en) * 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
FR2903695B1 (fr) * 2006-07-13 2008-10-24 Merck Sante Soc Par Actions Si Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
HK1157784A1 (en) 2012-07-06
WO2009152909A1 (en) 2009-12-23
MY155695A (en) 2015-11-13
JP2011524384A (ja) 2011-09-01
IL209421A (en) 2015-06-30
ES2436195T3 (es) 2013-12-27
US20120322806A1 (en) 2012-12-20
CN102066342A (zh) 2011-05-18
AU2009259754B2 (en) 2014-10-02
EA020236B1 (ru) 2014-09-30
EP2285786B1 (en) 2013-10-09
EP2285786A1 (en) 2011-02-23
DK2285786T3 (da) 2013-11-04
CN102066342B (zh) 2013-09-04
SI2285786T1 (sl) 2014-02-28
AR072148A1 (es) 2010-08-11
EA201100007A1 (ru) 2011-08-30
JP5596676B2 (ja) 2014-09-24
BRPI0915064B1 (pt) 2019-10-08
IL209421A0 (en) 2011-01-31
CA2728018A1 (en) 2009-12-23
PT2285786E (pt) 2014-01-07
ECSP11010760A (es) 2011-02-28
AU2009259754A1 (en) 2009-12-23
BRPI0915064B8 (pt) 2021-05-25
KR20110017455A (ko) 2011-02-21
CO6321252A2 (es) 2011-09-20
CA2728018C (en) 2016-10-11
CY1114737T1 (el) 2016-12-14
US8674097B2 (en) 2014-03-18
HRP20131069T1 (hr) 2013-12-20
BRPI0915064A2 (pt) 2015-10-27
US20110130404A1 (en) 2011-06-02
MX2010013577A (es) 2010-12-21
KR101641391B1 (ko) 2016-07-20
US8329698B2 (en) 2012-12-11
NZ590503A (en) 2012-08-31

Similar Documents

Publication Publication Date Title
IL209421A0 (en) Quinoxalinedione derivatives
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
IL210406A0 (en) Pyrrolopyridinylpyrimidin - 2 - ylamine derivatives
ZA201102449B (en) Morpholinopurine derivatives
EP2269993A4 (en) 2-aminoquinazoline DERIVATIVE
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
ZA201005769B (en) Bicycloamine derivative
IL208623A0 (en) Cyclopentylacrylamide derivative
ZA201101236B (en) New 2-amidothiadiazole derivatives
ZA201100948B (en) Acylaminobenzamide derivatives
IL213424A0 (en) Quinazolinamide derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL207192A0 (en) Substituted heteroarylamide diazepinopyrimidone derivatives
ZA201005381B (en) Substituted heteroarylamide oxazepinopyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
ZA201006992B (en) Hydroxyquinoxalinecarboxamide derivative
TWI368572B (en) Printing-table arrangement
IL212683A0 (en) Biphenylacetamide derivative
IL213051A0 (en) Difluorophenyldiacylhydrazide derivatives
GB2463042B (en) Stabalizer arrangement
EP2311810A4 (en) AMIDINE DERIVATIVE
GB0816145D0 (en) a-Galactosylceramide derivatives